查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1609137

发作性睡病治疗药物市场：按类型、治疗药物类型 - 全球预测 2025-2030

Narcolepsy Drugs Market by Type (Narcolepsy with Cataplexy, Narcolepsy without Cataplexy, Secondary Narcolepsy), Therapeutics Type (Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Sodium Oxybate) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年发作性睡病治疗药物市场价值为30.5亿美元，预计到2024年将达到32.8亿美元，复合年增长率为6.77%，到2030年将达到48.3亿美元。

发作性睡病药物是针对慢性神经系统疾病的标靶治疗，这些疾病患者无法调节睡眠-觉醒週期，导致白天过度嗜睡、猝倒和夜间睡眠障碍。对这些药物的需求源于人们对发作性睡病对生活品质影响的认识的提高以及对有效管理策略的需要。它的用途各不相同，包括用于解决白天嗜睡的兴奋剂、用于控制猝倒的抗忧郁症以及用于解决多种症状的羟丁酸钠。最终用途范围涵盖医院、诊所和居家照护等医疗保健环境，重点是个人化护理。发作性睡病药物市场的关键成长要素包括诊断病例数量的增加、改善药物传递的技术进步以及医疗保健成本的上升。副作用较少的新治疗方法的开发正在被推动，透过个人化医疗和生物技术的创新，潜在的商机正在扩大。持续的监管支援以及人工智慧在药物开发研究中的整合进一步强化了市场格局。阻碍成长的挑战包括高昂的药品成本、潜在的副作用、欠发达地区的意识低下以及减缓新治疗方法推出的严格监管障碍。非侵入性药物传递系统（例如经皮吸收贴片）以及了解发作性睡病遗传倾向的研究还有创新开拓。公司应专注于策略联盟、广泛的临床试验和强有力的定价策略，以实现可负担性。市场是动态的，需要适应快速的科学进步和不断变化的消费者态度，要求相关人员保持敏捷和知情。透过教育宣传活动和与监管机构的合作解决限制可以帮助优化繁琐的路线并提高产品的可及性和更广泛的接受度。随着市场的发展，结合永续实践和数位健康整合可以为公司提供可行的见解和竞争优势。

主要市场统计
基准年[2023] 30.5亿美元
预计年份 [2024] 32.8亿美元
预测年份 [2030] 48.3亿美元
复合年增长率（%） 6.77%

市场动态：快速发展的发作性睡病药物市场的关键市场洞察

供给和需求的动态交互作用正在改变发作性睡病药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 发作性睡病患病率增加
    • 提高消费者对发作性睡病药物益处的认识
    • 睡眠相关疾病的医疗支出增加
  • 市场限制因素
    • 发作性睡病药物的副作用
  • 市场机会
    • 政府努力开发治疗发作性睡病的药物
    • 开发新药的持续研究开发活动
  • 市场挑战
    • 对新兴经济体的渗透延迟

波特的五力：驾驭发作性睡病药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解发作性睡病药物市场的外部影响

外部宏观环境因素在塑造发作性睡病治疗药物市场的表现动态中起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解发作性睡病治疗药物市场的竞争状况

发作性睡病治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵发作性睡病治疗市场供应商的绩效评估

FPNV 定位矩阵是评估发作性睡病治疗药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，为发作性睡病治疗药物市场的成功指明道路

发作性睡病治疗药物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 发作性睡病患病率增加
      • 提高消费者对发作性睡病药物益处的认识
      • 睡眠相关疾病的医疗费用增加
    • 抑制因素
      • 发作性睡病药物的副作用
    • 机会
      • 政府努力开发治疗发作性睡病的药物
      • 开发新药的持续研究和开发活动
    • 任务
      • 新兴经济体渗透率低
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章发作性睡病治疗药物市场：依类型

  • 发作性睡病和猝倒症
  • 不伴猝倒的发作性睡病
  • 次发性睡病

第七章发作性睡病治疗药物市场（依治疗药物类型）

  • 中枢神经系统兴奋剂
  • 选择性血清素再回收抑制剂
  • 羟丁酸钠
  • 三环抗忧郁药物

第八章美洲发作性睡病药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区发作性睡病治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲的发作性睡病药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Apotex Inc.
  • Aurobindo Pharma Ltd.
  • Avadel Pharmaceuticals Plc
  • Axsome Therapeutics Inc.
  • Cadila Pharmaceuticals Ltd.
  • Don Valley Pharmaceuticals
  • Graymark Healthcare Inc.
  • Jabs Biotech Pvt. Ltd.
  • Jazz Pharmaceuticals PLC
  • Luckys Pharma Pvt. Ltd.
  • Midas Pharma GmbH
  • Orbion Pharmaceuticals Pvt. Ltd.
  • Shionogi and Co. Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • XWPharma Ltd.
Product Code: MRR-62667ADF9625

The Narcolepsy Drugs Market was valued at USD 3.05 billion in 2023, expected to reach USD 3.28 billion in 2024, and is projected to grow at a CAGR of 6.77%, to USD 4.83 billion by 2030.

Narcolepsy drugs are targeted treatments for a chronic neurological disorder characterized by an inability to regulate sleep-wake cycles, resulting in excessive daytime sleepiness, cataplexy, and disturbed nocturnal sleep. The necessity for these drugs arises from the growing awareness of narcolepsy's impact on the quality of life, necessitating effective management strategies. Their applications vary, including stimulants for combating daytime lethargy, antidepressants for controlling cataplexy, and sodium oxybate for addressing multiple symptoms. The end-use scope ranges across healthcare settings like hospitals, clinics, and homecare, emphasizing personalized care. Key growth influencers in the narcolepsy drug market include a rise in diagnosed cases, advancements in technology for better drug delivery, and increased healthcare expenditure. There's a push towards developing novel therapies with fewer side effects, opening potential opportunities in personalized medicine and biotech innovations. Continuous regulatory support and integration of artificial intelligence in research for drug development further enhance the market landscape. Challenges hindering growth include the high cost of drugs, potential side effects, limited awareness in underdeveloped regions, and stringent regulatory hurdles that delay the introduction of new therapies. Innovating with non-invasive drug delivery systems, such as transdermal patches, and furthering research into understanding genetic predispositions in narcolepsy are avenues ripe for exploration. Companies should focus on strategic alliances, expansive clinical trials, and robust pricing strategies to enhance affordability. The market is dynamic, necessitating adaptability to rapid scientific advancements and shifts in consumer awareness, requiring stakeholders to remain agile and informed. Addressing limitations through education campaigns and collaboration with regulatory entities can optimize onerous pathways, enhancing product accessibility and fostering broader acceptance. As the market evolves, embracing sustainable practices and digital health integration could provide businesses with actionable insights and a competitive edge.

KEY MARKET STATISTICS
Base Year [2023] USD 3.05 billion
Estimated Year [2024] USD 3.28 billion
Forecast Year [2030] USD 4.83 billion
CAGR (%) 6.77%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Narcolepsy Drugs Market

The Narcolepsy Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of narcolepsy disorder
    • Growing consumer awareness towards benefits of narcolepsy drugs
    • Rising healthcare spending for sleep related disorders
  • Market Restraints
    • Side effects of narcolepsy drugs
  • Market Opportunities
    • Governmental initiatives for narcolepsy drug development
    • Ongoing research and development activities for novel drug development
  • Market Challenges
    • Less penetration across developing economies

Porter's Five Forces: A Strategic Tool for Navigating the Narcolepsy Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Narcolepsy Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Narcolepsy Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Narcolepsy Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Narcolepsy Drugs Market

A detailed market share analysis in the Narcolepsy Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Narcolepsy Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Narcolepsy Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Narcolepsy Drugs Market

A strategic analysis of the Narcolepsy Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Narcolepsy Drugs Market, highlighting leading vendors and their innovative profiles. These include Apotex Inc., Aurobindo Pharma Ltd., Avadel Pharmaceuticals Plc, Axsome Therapeutics Inc., Cadila Pharmaceuticals Ltd., Don Valley Pharmaceuticals, Graymark Healthcare Inc., Jabs Biotech Pvt. Ltd., Jazz Pharmaceuticals PLC, Luckys Pharma Pvt. Ltd., Midas Pharma GmbH, Orbion Pharmaceuticals Pvt. Ltd., Shionogi and Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and XWPharma Ltd..

Market Segmentation & Coverage

This research report categorizes the Narcolepsy Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Narcolepsy with Cataplexy, Narcolepsy without Cataplexy, and Secondary Narcolepsy.
  • Based on Therapeutics Type, market is studied across Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Sodium Oxybate, and Tricyclic Antidepressants.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of narcolepsy disorder
      • 5.1.1.2. Growing consumer awareness towards benefits of narcolepsy drugs
      • 5.1.1.3. Rising healthcare spending for sleep related disorders
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects of narcolepsy drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Governmental initiatives for narcolepsy drug development
      • 5.1.3.2. Ongoing research and development activities for novel drug development
    • 5.1.4. Challenges
      • 5.1.4.1. Less penetration across developing economies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Narcolepsy Drugs Market, by Type

  • 6.1. Introduction
  • 6.2. Narcolepsy with Cataplexy
  • 6.3. Narcolepsy without Cataplexy
  • 6.4. Secondary Narcolepsy

7. Narcolepsy Drugs Market, by Therapeutics Type

  • 7.1. Introduction
  • 7.2. Central Nervous System Stimulants
  • 7.3. Selective Serotonin Reuptake Inhibitor
  • 7.4. Sodium Oxybate
  • 7.5. Tricyclic Antidepressants

8. Americas Narcolepsy Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Narcolepsy Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Narcolepsy Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Apotex Inc.
  • 2. Aurobindo Pharma Ltd.
  • 3. Avadel Pharmaceuticals Plc
  • 4. Axsome Therapeutics Inc.
  • 5. Cadila Pharmaceuticals Ltd.
  • 6. Don Valley Pharmaceuticals
  • 7. Graymark Healthcare Inc.
  • 8. Jabs Biotech Pvt. Ltd.
  • 9. Jazz Pharmaceuticals PLC
  • 10. Luckys Pharma Pvt. Ltd.
  • 11. Midas Pharma GmbH
  • 12. Orbion Pharmaceuticals Pvt. Ltd.
  • 13. Shionogi and Co. Ltd.
  • 14. Takeda Pharmaceutical Co. Ltd.
  • 15. Teva Pharmaceutical Industries Ltd.
  • 16. XWPharma Ltd.

LIST OF FIGURES

  • FIGURE 1. NARCOLEPSY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. NARCOLEPSY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. NARCOLEPSY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. NARCOLEPSY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NARCOLEPSY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NARCOLEPSY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY NARCOLEPSY WITH CATAPLEXY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY NARCOLEPSY WITHOUT CATAPLEXY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY SECONDARY NARCOLEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY SODIUM OXYBATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. NARCOLEPSY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. NARCOLEPSY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023